- Home
- CLNN vs CALC Comparison
CLNN vs CALC Comparison
Compare CLNN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- CALC
- Stock Information
- Founded
- CLNN 2012
- CALC 2011
- Country
- CLNN United States
- CALC United States
- Employees
- CLNN N/A
- CALC N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- CALC Health Care
- Exchange
- CLNN Nasdaq
- CALC Nasdaq
- Market Cap
- CLNN 23.1M
- CALC 22.9M
- IPO Year
- CLNN N/A
- CALC N/A
- Fundamental
- Price
- CLNN $3.76
- CALC $1.56
- Analyst Decision
- CLNN Strong Buy
- CALC Strong Buy
- Analyst Count
- CLNN 5
- CALC 3
- Target Price
- CLNN $40.00
- CALC $16.33
- AVG Volume (30 Days)
- CLNN 141.3K
- CALC 25.5K
- Earning Date
- CLNN 08-06-2025
- CALC 08-11-2025
- Dividend Yield
- CLNN N/A
- CALC N/A
- EPS Growth
- CLNN N/A
- CALC N/A
- EPS
- CLNN N/A
- CALC N/A
- Revenue
- CLNN $350,000.00
- CALC N/A
- Revenue This Year
- CLNN N/A
- CALC N/A
- Revenue Next Year
- CLNN $1,753.57
- CALC N/A
- P/E Ratio
- CLNN N/A
- CALC N/A
- Revenue Growth
- CLNN N/A
- CALC N/A
- 52 Week Low
- CLNN $2.28
- CALC $1.43
- 52 Week High
- CLNN $7.59
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CLNN 52.37
- CALC 32.78
- Support Level
- CLNN $4.12
- CALC $1.48
- Resistance Level
- CLNN $4.40
- CALC $1.79
- Average True Range (ATR)
- CLNN 0.26
- CALC 0.12
- MACD
- CLNN -0.06
- CALC -0.02
- Stochastic Oscillator
- CLNN 7.89
- CALC 0.00
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.